
Oncology NEWS International
- Oncology NEWS International Vol 17 No 4
- Volume 17
- Issue 4
Tremelimumab trial discontinued
Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy.
NEW YORK-Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. “We will continue to assess the study data to understand the clinical benefit seen in some patients who received tremelimumab,” said Pfizer’s Charles Baum, MD, PhD.
Articles in this issue
over 18 years ago
Proton therapy training offeredover 18 years ago
Editor of Blood reviews a very bloody movieover 18 years ago
Artists take note: Oncology on Canvas accepting entriesover 18 years ago
PET affects treatment in over one-third of cancer casesover 18 years ago
Expanded use of Axxent approvedover 18 years ago
Gardasil supplemental application gets priority review designationover 18 years ago
Optical tomo/US monitors adjuvant chemo responseover 18 years ago
GIST patients resistant to imatinib/sunitinib respond to sorafenibover 18 years ago
Sunitinib plus a taxane active in advanced breast cancerover 18 years ago
Stanford V yields excellent outcomes in bulky, advanced HL





























































